Clinical Trial Update: A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI) [Phase 4]

View source ↗

Summary

Phase 4 study evaluating safety of a single IV dose of oritavancin (Orbactiv) in participants on chronic warfarin therapy for acute bacterial skin and skin stru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infection

Drugs mentioned

• Orbactiv (oritavancin)

Snippet

Sponsor: The Medicines Company | Conditions: Acute Bacterial Skin and Skin Structure Infection | Phase 4 | Status: COMPLETED | Results posted: 2023-12-20